# A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy.

> **NCT07037394** · PHASE4 · COMPLETED · sponsor: **Qurratul Ain Jamil** · enrollment: 252 (actual)

## Conditions studied

- Overt Hepatic Encephalopathy

## Interventions

- **DRUG:** Probiotic plus lactulose
- **DRUG:** Rifaximin plus lactulose
- **DRUG:** L-ornithine-L-aspartate plus latulose
- **DRUG:** Lactulose

## Key facts

- **NCT ID:** NCT07037394
- **Lead sponsor:** Qurratul Ain Jamil
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-02
- **Primary completion:** 2025-04-21
- **Final completion:** 2025-04-30
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07037394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07037394, "A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07037394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*